Management of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Patient with Cutaneous Involvement

Dr. McCloskey provides a brief overview of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including the clinical hallmarks of the disease and the challenges in recognizing and diagnosing this rare condition.

Dr. McCloskey discusses the appropriateness of the initial therapy (tagraxofusp) based on NCCN guidelines, as well as the benefits and limitations of current treatment regimens for BPDCN.

Dr. McCloskey explores the mechanism of action and potential efficacy of tagraxofusp in the treatment of BPDCN.

Dr. McCloskey discusses the recent clinical trial results, such as the CADENZA trial, on the efficacy and safety of tagraxofusp in BPDCN patients.

Dr. McCloskey examines the potential of anti-CD123 CAR T-cell therapy for BPDCN, including the main challenges and limitations of this therapeutic approach.

Dr. McCloskey discusses the general principles and practices for monitoring and mitigating adverse events, particularly capillary leak syndrome (CLS), in BPDCN patients treated with systemic agents like tagraxofusp.

Dr. McCloskey explores how various treatments for BPDCN impact the quality of life of patients, both in terms of disease response and side effects.

Dr. McCloskey discusses the limitations of current treatment options for BPDCN, as well as the emerging research and data that are most anticipated in the field.